Research programme: glutamate modulating agents - Biohaven Pharmaceutical Holding Company
Latest Information Update: 06 Oct 2016
At a glance
- Originator Rutgers
- Developer Biohaven Pharmaceutical Holding Company
- Class Antineoplastics
- Mechanism of Action Glutamate modulators; Glutamate receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer